Owlet, Inc. announced strong first quarter 2024 results with revenue of approximately $14.8 million, up 37% year over year, gross margin at 44.4%, and net income of $3.3 million. The company's adjusted EBITDA loss improved by 46% year over year. Owlet's CEO highlighted the positive feedback on their medical devices and increased demand for their products, projecting continued success in 2024.
Q1 revenue increased by 37% year over year to approximately $14.8 million. Gross margin stood at 44.4%, up 570 basis points year over year. Net income for Q1 was approximately $3.3 million, a significant improvement from the net loss of $11.9 million in the previous year. Adjusted EBITDA loss improved by approximately 46% year over year. Positive feedback on the Dream Sock and Dream Duo products following FDA clearance led to a 60% increase in consumer demand. Owlet surpassed 2 million infants monitored, indicating strong market position and operational health for continued success.
Operating loss was approximately $5.7 million for Q1 2024. Adjusted net loss per share was ($0.39) for the first quarter of 2024, compared to adjusted net loss per share of ($1.10) for the same period in 2023. Operating expenses, including stock-based compensation, were approximately $12.3 million for Q1 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.